The influence of cystathionine on neurochemical quantification in brain tumor in vivo magnetic resonance spectroscopy
Francesca Branzoli1,2, Dinesh K Deelchand3, Roberto Liserre4, Pietro Luigi Poliani5, Lucia Nichelli6, Marc Sanson2,7, Stéphane Lehéricy1,2,6, and Małgorzata Marjańska3
1Center for Neuroimaging Research - CENIR, Paris Brain Institute - ICM, Paris, France, 2UMR S 1127, Inserm U 1127, CNRS UMR 7225, Sorbonne University, Paris, France, 3Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, MN, United States, 4Department of Radiology, Neuroradiology Unit, ASST Spedali Civili University Hospital, Brescia, Italy, 5Pathology Unit, Department of Molecular and Translational Medicine, Brescia University, Brescia, Italy, 6Department of Neuroradiology, Pitié Salpêtrière hospital, Paris, France, 7Department of Neurology 2, Pitié Salpêtrière hospital, Paris, France
We reported the ability of PRESS to detect cystathionine in vivo in patients with glioma and the effect of the omission of cystathionine on the quantification of the full neurochemical profile. We showed that the omission of cystathionine from analysis leads to severe biases on the quantification of other metabolites involved in cancer metabolism, e.g., aspartate, betaine, citrate, GABA and serine. Because cystathionine was shown to accumulate preferentially in gliomas with 1p/19q codeletion, omission of this metabolite may lead to the wrong evaluation of other metabolic changes in these tumors.
This abstract and the presentation materials are available to members only;
a login is required.